With a median follow-up of @ months ( IQR @-@ ) , median progression-free survival was @ months ( @ % CI @-@ ) in the cediranib group and @ months ( @-@ ) in the placebo group ( HR @ , @ % CI @-@ , @ % CI @-@ ; p = @ ) .